ETF Update: Pharma ETFs, Commodity ETFs, Carry Trade
Success Of Cancer Vaccines Could Have Pharma ETFs Feeling Good
With drug makers making a push for cervical cancer vaccination, the industry is quickly growing, and certain ETFs can capture this growth.
In a New York Times article, Elisabeth Rosenthal examines how over the past two years, cervical cancer has gone from an obscure disease mostly in poor nations to a great concern in many western countries.
Two vaccines have been approved and released over the past two years. Over this period, tens of millions of girls throughout the United States and Europe have been vaccinated against cervical cancer. In many countries, the vaccines were recommended for universal use among females between the ages of 11 and 26. The vaccines include Gardasil, from Merck (MRK), and Cervarix, a GlaxoSmithKline (GSK) product.
As this market grows at an alarming rate, the vaccines have appealed to not only potential recipients and humanitarians, but politicians as well. The remarkably quick transition of the vaccines in the United States and Europe shows the success of what manufacturers call education and critics call marketing.
As investment in these vaccines increases, award-winning advertising has been utilized to promote these innovations. The impact has been so large, 41 states have passed or have begun considering legislation on cervical cancer. Virginia has made the shots mandatory for girls before entering school, which takes effect in 2009.
As even the critics of the marketing admit to the benefits of the vaccines, many questions remain unanswered about both treatments. Questions pertaining to the length of immunity and potential side effects have nagged the vaccines.
However, 16 million doses have already been distributed domestically by Merck. This left both the FDA and CDC saying that “by chance alone some serious adverse effects and deaths” will occur because of the large population these 16 million doses were administered to.
Even though some questions remain pertaining to the long-term effects and immunity of the vaccines, the market for these treatments is vast and potentially very lucrative. Some ETFs that could weigh in on this action include:
- HealthShares Cancer (HHK), is up 1.5% year-to-date with top holdings in Vertex Pharmaceuticals (VRTX), APP Pharmaceuticals, Fresenius, and Onyx Pharmaceuticals (ONXX).
- Pharmaceutical HOLDRs (PPH), is down 9.8% year-to-date with top holdings in Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Merck, and Pfizer (PFE).
- PowerShares Dynamic Pharmaceuticals (PJP), is up .06% year-to-date with top holdings in Genentech (DNA), Wyeth (WYE), Merck, and Johnson & Johnson.
- SPDR S&P Pharmaceuticals (XPH), is up 3.6% year-to-date with top holdings in Barr Pharmaceuticals (BRL), Forest Laboratories (FRX), King Pharmaceuticals, and Merck.
- iShares Dow Jones US Pharmaceuticals (IHE), is down 1.3% year-to-date with top holdings in Pfizer, Merck, Johnson & Johnson, and Abbott Laboratories.
When It Comes to Taxes, Commodity ETFs Are a Different Breed
Now that commodities have come down from their recent highs, are you tempted to go in on a market dip with a focused ETF?
Commodity ETFs are popular, no doubt, especially given the bull run they’ve had this year, garnering nearly $20 billion in net inflows, reports Paulette Miniter for Smart Money, and Morgan Stanley analyst Paul Mazzilli says assets now stand at $30 billion.
ETFs such as United States Oil (USO) is the first pure oil play, with $1 billion in assets, and SPDR Gold Shares (GLD) took in an astounding $19 billion thus far. Most retail investors should understand, however, that the tax treatment for commodity funds is a little different than the usual.
While commodity ETFs do not hold actual stocks, they do own either the actual physical commodity itself, or a futures contract or a derivative. So, even if you do not sell the ETF, you will owe the government 60% of your gains taxed at 15% for long term and 40% of your gains at the going rate of your general income.
When you invest in the actual physical commodity with a fund such as iShares COMEX Gold Trust (IAU), the IRS taxes them as collectibles, earning them a higher long-term gain rate at 28%, not 15% charged to stocks.
If and when you decide to dip into the commodity ETF pool, just be aware of these facts and how taxes work when it comes to commodities, and consider them when making your decision.
The Carry Trade At Everyone’s Fingertips With An ETF
Institutional strategies are becoming more and more common for the individual investor, especially with the ETF explosion.
Take into account the carry trade: it is all about selling currencies at low interest rates and buying currencies with high interest rates, and then the investor benefits from the interest rate spread, reports Matthew Hougan for Index Universe.
PowerShares G10 Currency Harvest Fund (DBV) is an unleveraged ETF that invests in a steady pattern of long-term returns with low correlations to market fluctuations. Since its inception in September 2006, it’s up 8.2%. Year-to-date, it’s down 4.5%.
The index invests in U.S. dollars, euros, Japanese yen, Canadian dollars, Swiss franc, British pound, Australian dollars, New Zealand dollars, Norwegian krone, Swedish krona. The expense ratio is at 0.75%. The volatility is low in this ETF because the index takes long and short positions providing consistent and less volatile returns.
Throughout the year, the weightings of each commodity component in the index naturally changes, based on changes in the underlying futures prices.
Related Articles
|
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Trading Center
- Free E-Newsletters
- About Seeking Alpha
- About Us
- Contact Us
- What's New
- Readers Feedback
- Advertise With Us
- Contributors
- Contribute an Article
- Feature Your Book
- Our Contributors
- Anonymous Contributions
- Dispute an Article?
- Legal
- Terms of Use
- Privacy
- Copyright
This article has 3 comments:
- ksmithdc
- 92 Comments
My Website
Aug 24 11:08 AM- omooc
- 210 Comments
My Website
Aug 24 09:48 PM- ikkyu
- 106 Comments
Aug 25 11:20 AMYou have repeated Hougan's error. DBV is leveraged 2:1. The prospectus probably should be read by "professionals.&q...
Cheers from Osaka,
John
More by Tom Lydon